Potential Cost-Effectiveness of Neratinib Following Trastuzumab Therapy for Treatment of Early-Stage Her2-Positive Breast Cancer
May 1, 2018, 00:00
10.1016/j.jval.2018.04.179
https://www.valueinhealthjournal.com/article/S1098-3015(18)30479-0/fulltext
Title :
Potential Cost-Effectiveness of Neratinib Following Trastuzumab Therapy for Treatment of Early-Stage Her2-Positive Breast Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30479-0&doi=10.1016/j.jval.2018.04.179
First page :
Section Title :
Open access? :
No
Section Order :
1025